Gastrointestinal Drugs Market Size, Share & Trends Analysis Report By Drug Class Type (Acid Neutralizers, Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Anti-inflammatory Drugs, Biologics, Others (Antispasmodic etc.)), By Route of Administration (Oral, Intravenous, Rectal), By Disorder Type (Gastro-esophageal Reflux Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global gastrointestinal drugs market size was valued at USD 71,658.01 million in 2022. It is estimated to reach USD 105,193.10 million by 2031, growing at a CAGR of 5.2% during the forecast period (2023–2031).

Many medications are available to alleviate gastrointestinal diseases' distress and accompanying symptoms. These remedies encompass both prescription and non-prescription drugs and conventional and unconventional agents. They cover many therapeutic options, from small molecules to complex macromolecules to enormous recombinant proteins. The realm of medications encompasses various classifications, each delineated by its specific purpose. Among these classifications, some drugs combat the distressing symptoms of nausea and vomiting, aptly referred to as antiemetics. There are also antidiarrheal agents which effectively combat the troublesome diarrhea condition. Drugs tailored to address acid peptic, irritable bowel syndrome, and inflammatory bowel disease in gastrointestinal health.

Highlights

• Acid Neutralizers dominate the drug class type segment
• Oral dominates the route of administration segment
• Gastro-Esophageal Reflux disease dominates the disorder-type segment
• North America is the highest shareholder in the global market

Market Dynamics

Global Market Drivers

Biologics Development

The market's expansion is driven by the ongoing development of innovative medications, exemplified by Janssen Pharmaceutical's approval of STELARA targeting the IL-12/IL-23 pathway for ulcerative colitis. Strategic initiatives like launching products in untapped markets, as seen with Takeda Pharmaceutical's introduction of Vedolizumab in India, contribute to market growth. The increasing incidence of gastrointestinal (GI) disorders in developing nations, notably India, which has a substantial population affected by inflammatory bowel disease (IBD), is also predicted to drive market expansion in the coming years due to the introduction of novel biologic therapies.

Rising Elderly Population

It is crucial to consider the user's comfort and ease of use when designing blood glucose test strips packaging. The main goal is to devise ways to package the test strips to make them as easy to use as possible. Often, tear strips are built into the package design, making it easy to open and get to the test strips quickly. Clear labels are very important because they tell people how to use the test strips properly in a way that is clear and easy to understand. This makes sure that people can follow the steps without getting confused.

Additionally, tamper-evident seals are used to give people confidence in the safety and reliability of the product and to show that the test strips have not been changed. Companies aim to simplify the use of blood glucose test strips and enhance the user experience by highlighting simple-to-use package features. People prefer packing options that satisfy these needs because they emphasize utility and usability.

Global Market Restraint

High Cost of Raw Material Used in Manufacturer Gastrointestinal Drugs

The exorbitant cost of raw materials utilized in the manufacturing process impedes the growth of the market. The expenses of sourcing and processing these materials significantly drive production costs, resulting in expensive final drugs for manufacturers and consumers. Therefore, gastrointestinal drugs have become less affordable and their accessibility is limited, particularly in underprivileged regions with strained healthcare resources.

Global Market Opportunities

Rising Prevalence of Gastrointestinal Diseases Around the World

The global market for gastrointestinal medications is expanding rapidly due to the rising frequency of gastrointestinal illnesses globally. GI illnesses are becoming more common because of changes in food, inactivity, and an older population. This results in a growing need for effective medicines, which has resulted in the proliferation and innovation of gastrointestinal pharmaceuticals. Significant investment in scientific research has aided in the creation of novel therapies.

Furthermore, rising knowledge of the efficacy of these treatments and the healing process has aided in the market's rise. Technological improvements have improved diagnostic, monitoring, and treatment options, bringing up new prospects for significant market growth in the next years. These factors lead to increasing demand for gastrointestinal medications, propelling the market ahead.

Regional Analysis

Based on region, the global gastrointestinal drugs market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global gastrointestinal drugs market shareholder and is predicted to grow significantly during the forecast period. North America is the leading revenue-generating region in the market, primarily due to favorable reimbursement policies that benefit individuals with gastrointestinal issues by ensuring access to necessary medications. Moreover, the region is experiencing a notable increase in the prevalence of chronic diseases, where gastrointestinal problems often present as prominent symptoms. In particular, North America outperformed other regions in 2016, with a significant market share of over 41%. Sales of gastrointestinal drugs are anticipated to soar in the near future due to North America's steadily aging population. These combined factors contribute to the ongoing advancements and growth of the market in the region.

The Asia-Pacific region is expected to hold the second-largest share of the gastrointestinal drug market. This is due to several factors driving its growth. A significant development in healthcare and medical infrastructure across the region has led to improved diagnosis, treatment, and management of gastrointestinal syndromes and diseases. This progress is supported by increased public and private investments focused on technological advancements and life sciences research. These investments contribute to the innovation and development of more effective gastrointestinal drugs, bolstering market growth.

Furthermore, regional economies, particularly China and India, are expected to play a pivotal role in driving the global gastrointestinal drug market. With their large populations, rapid urbanization, changing lifestyles, and increased healthcare spending, the demand for advanced treatments and medicinal processes for gastrointestinal disorders is rising. As a result, the Asia Pacific market is expected to thrive, driven by the growing need for gastrointestinal drugs in these emerging economies.

Europe plays a significant role in the market, owing to various factors that contribute to its prominence. The area benefits from a well-established healthcare infrastructure and substantial healthcare expenditure, which enables advanced treatment options and widespread access to gastrointestinal medications. Europe's aging population, more susceptible to gastrointestinal disorders, drives the demand for effective pharmaceutical interventions.

Europe also demonstrates a strong commitment to research and development, supported by favorable regulatory frameworks, fostering innovation and the introduction of novel drugs. Moreover, increasing awareness regarding gastrointestinal health and the availability of state-of-the-art diagnostic technologies contribute to the market's growth in the region. Overall, Europe's favorable healthcare landscape, focus on R&D, and rising awareness position it as a significant player in the market, presenting promising opportunities for future market expansion.

Latin America and the Middle East and Africa region demonstrate promising growth potential in the market. Latin America's market is propelled by factors like the increasing prevalence of gastrointestinal disorders, rising healthcare expenditure, and the ongoing enhancement of healthcare infrastructure. The region's large population, evolving lifestyles, and dietary patterns contribute to the growing burden of gastrointestinal diseases, driving the demand for effective medications. The Middle East and Africa market is stimulated by the escalating incidence of gastrointestinal disorders, expanding healthcare infrastructure, and a growing focus on gastrointestinal health awareness.

Additionally, government initiatives to improve healthcare facilities and investments in healthcare technology further bolster market growth in these regions. Although certain challenges, such as limited healthcare access in some areas, exist, efforts are being made to overcome these obstacles and expand the availability of gastrointestinal drugs. Tregion presents favorable opportunities for market expansion, fueled by the increasing burden of gastrointestinal diseases and ongoing efforts to enhance healthcare infrastructure and raise awareness.

Segmental Analysis

The global gastrointestinal drugs market is bifurcated into drug class type, route of administration, disorder type, and distribution channel.

Based on the drug class type, the global market is divided into acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics, and others (antispasmodic, etc.). 

The acid neutralizers segment is the highest contributor to the market share and is expected to grow significantly during the forecast period. The acid neutralizers segment holds a prominent position in the global market, establishing its dominance with a substantial market share. The segment's success can be attributed to various factors, most notably the cost efficiency of acid neutralizers, which have played a pivotal role in driving their impressive growth and widespread acceptance in the market. Acid neutralizers offer an effective and affordable solution for managing gastrointestinal disorders, making them highly preferred by patients and healthcare providers.

Additionally, they have established themselves as a top choice thanks to their ability to treat gastrointestinal conditions that are affordably caused by excess acid. In the future, acid neutralizers are anticipated to continue to generate strong revenue compared to other drug-class segments. This enduring popularity is rooted in their proven efficacy, easy accessibility, and affordability, making them a reliable choice for individuals seeking relief. As a result, the acid neutralizers segment is poised for sustained growth and is likely to maintain its significant market presence in the global market.

Based on the route of administration, the global market is divided into oral, intravenous, and rectal.

The oral segment owns the largest market share and is predicted to grow significantly over the forecast period. It is the most widely used and convenient method of delivering gastrointestinal medications to patients. Oral administration involves the ingestion of tablets, capsules, liquids, or suspensions, providing various options for drug formulations. This route offers several advantages, including easy administration, improved patient compliance, and a wide range of available medication forms. The digestive system efficiently absorbs gastrointestinal drugs taken orally and can be distributed throughout the body, effectively treating various gastrointestinal conditions.

Additionally, the oral route offers dosage flexibility, allowing healthcare practitioners to tailor the drug to the requirements of individual patients. Based on a thorough examination of the available evidence, oral administration remains the preferred approach for administering gastrointestinal medicines. This is anticipated to grow and maintain a dominating position in the market for the foreseeable future.

Based on disorder type, the global market is segmented into gastro-esophageal reflux disease, irritable bowel syndrome, and inflammatory bowel disease.

The gastro-esophageal reflux disease segment owns the largest market share and is anticipated to grow significantly during the forecast period. It becomes clear that Gastro-esophageal reflux disease (GERD) dominates the market for gastrointestinal drugs when considering the different disorders that exist within it. GERD, a condition that pervades our society, manifests as the insidious backflow of stomach acid into the delicate esophagus. This unwelcome intrusion gives rise to many distressing symptoms, including the fiery sensation of heartburn, the unsettling experience of regurgitation, and the discomforting ache in the chest. In addition, the management and treatment of GERD require a steadfast commitment, as it is a condition that persists over the long haul. Its commanding presence is expected to endure, firmly establishing its dominance in the market for the foreseeable future.

Based on the distribution channel, the global market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment dominates the largest market and is predicted to grow significantly over the forecast period. Hospital pharmacies play a vital role in managing and distributing medications for various gastrointestinal disorders, including GERD. GERD is a chronic condition requiring ongoing treatment, so hospital pharmacies serve a significant patient population seeking relief from GERD symptoms. These pharmacies stock and supply a wide range of gastrointestinal drugs, such as proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2 blockers), and antacids commonly prescribed for managing GERD. The GERD segment holds a dominant position in the market, specifically in hospital pharmacies, due to the high prevalence of GERD and the requirement for pharmaceutical interventions in hospital settings.

Recent Developments

• March 2023- Takeda invested approximately 100 billion yen to build a new plasma-derived therapies (PDTs) manufacturing facility in Osaka, Japan. This represents Takeda’s largest-ever investment in manufacturing capacity expansion in Japan.
• September 2022- Takeda launched the CDPATH program, which includes an innovative, validated personalized prognostic tool that uses blood tests to help predict the potential risk of developing serious Crohn’s disease-related complications within three years.